R H Earhart
Overview
Explore the profile of R H Earhart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Earhart R
Semin Oncol
. 1999 Dec;
26(5 Suppl 17):8-13.
PMID: 10604262
Docetaxel (Taxotere; Rhône-Poulenc Rorer, Collegeville, PA) is the second member of the taxane class of cytotoxic agents to reach clinical use. The development of docetaxel was remarkably rapid, from the...
2.
Valero V, Jones S, Von Hoff D, Booser D, Mennel R, Ravdin P, et al.
J Clin Oncol
. 1998 Oct;
16(10):3362-8.
PMID: 9779713
Purpose: To evaluate the efficacy and safety of docetaxel in patients with paclitaxel-resistant metastatic breast cancer (MBC). Patients And Methods: Docetaxel (100 mg/m2) was administered every 3 weeks to 46...
3.
Burris H, Dieras V, Tunca M, Earhart R, Eckardt J, Rodriguez G, et al.
Anticancer Drugs
. 1997 Jul;
8(6):588-96.
PMID: 9300573
Adozelesin, a synthetic analog of the antitumor antibiotic CC-1065, is a novel cytotoxic agent which inhibits DNA synthesis by binding to the minor groove of the DNA helix. Preclinical studies...
4.
Foster B, LoRusso P, Poplin E, Zalupski M, Valdivieso M, Wozniak A, et al.
Invest New Drugs
. 1996 Jan;
13(4):321-6.
PMID: 8824350
CC-1065 is a unique alkylating agent that preferentially binds in the minor groove of double-stranded DNA at adenine-thymine-rich sites. Although it has broad antitumor activity in preclinical models its development...
5.
Welch D, Aeed P, Earhart R, McClure S
Anticancer Res
. 1994 Sep;
14(5A):1743-51.
PMID: 7847807
The ability of tumor cell lines to form experimental pulmonary metastases is determined in part by characteristics which are stable over many cell generations; in part by characteristics that are...
6.
Fleming G, Ratain M, OBrien S, Schilsky R, Hoffman P, Richards J, et al.
J Natl Cancer Inst
. 1994 Mar;
86(5):368-72.
PMID: 8308929
Background: Adozelesin, a synthetic analogue of the antitumor antibiotic CC-1065, is the first of a class of potent sequence-specific alkylating agents to be brought to clinical trial. In preclinical in...
7.
Shamdas G, Alberts D, Modiano M, Wiggins C, Power J, Kasunic D, et al.
Anticancer Drugs
. 1994 Feb;
5(1):10-4.
PMID: 8186423
During a phase I clinical and pharmacologic trial, 26 patients with refractory solid tumors were treated with increasing doses of adozelesin by brief intravenous infusion every 3 weeks. Overall, adozelesin...
8.
Weiss G, Brown T, Kuhn J, Von Hoff D, Earhart R, Adams W, et al.
Invest New Drugs
. 1993 Feb;
11(1):17-27.
PMID: 8349432
Thirty-five patients with advanced refractory cancer were enrolled on this phase I study of menogaril administered orally every 4 weeks at dosages ranging from 85 mg/m2 to 625 mg/m2. An...
9.
Sarosdy M, Lamm D, Williams R, Moon T, Flanigan R, Crawford E, et al.
J Urol
. 1992 Jan;
147(1):31-3.
PMID: 1729546
A total of 34 patients with measurable superficial transitional cell cancer of the bladder entered into a phase 1, nonrandomized, noncomparative trial to assess the toxicity of the oral interferon...
10.
Williams M, Earhart R, Bailey H, McGovren J
Cancer Res
. 1990 Sep;
50(17):5475-80.
PMID: 2386952
Acivicin is an investigational amino acid antitumor antibiotic currently being evaluated in Phase II clinical trials. In humans acivicin causes reversible, dose-limiting central nervous system (CNS) effects including somnolence, ataxia,...